Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- About
Oaktree Acquisition Corp. III Life Sciences Class A Ordinary Share (OACC)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: OACC (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
0 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
Analysis of Past Performance
Type Stock | Historic Profit 0.78% | Avg. Invested days 42 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  5.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/14/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 257.94M USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta - | 52 Weeks Range 9.95 - 10.85 | Updated Date 06/29/2025 |
52 Weeks Range 9.95 - 10.85 | Updated Date 06/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) - |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) - | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 256669950 | Price to Sales(TTM) - |
Enterprise Value 256669950 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding 19783000 | Shares Floating 18332353 |
Shares Outstanding 19783000 | Shares Floating 18332353 | ||
Percent Insiders - | Percent Institutions 82.19 |
Upturn AI SWOT
Oaktree Acquisition Corp. III Life Sciences Class A Ordinary Share
Company Overview
History and Background
Oaktree Acquisition Corp. III Life Sciences Class A Ordinary Share was a special purpose acquisition company (SPAC) focused on the life sciences sector. SPACs are shell corporations listed on an exchange with the purpose of acquiring a private company, thereby making it public without going through the traditional IPO process. Oaktree Acquisition Corp. III Life Sciences Class A Ordinary Share is no longer trading.
Core Business Areas
Leadership and Structure
As a SPAC, the leadership team typically consists of experienced investment professionals whose expertise lie in identifying attractive acquisition targets.
Top Products and Market Share
Key Offerings
Market Dynamics
Industry Overview
The SPAC market experienced periods of boom and bust. The life sciences industry is generally considered innovative and high-growth, but also high-risk.
Positioning
Oaktree Acquisition Corp. III Life Sciences Class A Ordinary Share positioned itself to provide a promising private life sciences company with a quicker route to public markets. Oaktree's brand lent credibility.
Total Addressable Market (TAM)
The TAM was the market capitalization of potential target companies in the life sciences sector. The exact figure is dynamic and difficult to quantify without knowing the specific targets considered. Oaktree's positioning was aimed at accessing a portion of this TAM by providing an alternative public offering path.
Upturn SWOT Analysis
Strengths
- Experienced management team (Oaktree Capital Management)
- Access to capital
- Potential for quick public listing for target company
Weaknesses
- Dependence on finding suitable acquisition target
- Market volatility affecting SPAC valuations
- Risk of not completing an acquisition
Opportunities
- Growing life sciences sector
- Increasing demand for SPACs as alternative IPO route
- Potential for high returns if acquisition is successful
Threats
- Increased regulatory scrutiny of SPACs
- Competition from other SPACs
- Deterioration of market conditions
- Failure to find a suitable target.
Competitors and Market Share
Key Competitors
Competitive Landscape
The competitive landscape consisted of other SPACs seeking to acquire companies in the life sciences sector. Oaktree's main advantage was brand reputation.
Growth Trajectory and Initiatives
Historical Growth: N/A, pre-acquisition SPACs do not have meaningful historical growth in terms of revenue or earnings.
Future Projections: Future growth depended entirely on the success of the acquired company (if one occurred) and broader market factors.
Recent Initiatives: Identifying and negotiating with potential acquisition targets was the primary initiative.
Summary
Oaktree Acquisition Corp. III Life Sciences Class A Ordinary Share was a SPAC formed to acquire a company in the life science industry. As a SPAC, its financial performance depended on finding a suitable target company. The company's success was determined by the valuation and operational performance of the acquired company after the merger was complete. The competitive landscape was made up of other SPACs competing for targets.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings
- Market analysis reports
- Financial news sources
Disclaimers:
This analysis is based on publicly available information and is not financial advice. The performance of Oaktree Acquisition Corp. III Life Sciences Class A Ordinary Share was dependent on its ability to identify and acquire a suitable target company.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Oaktree Acquisition Corp. III Life Sciences Class A Ordinary Share
Exchange NASDAQ | Headquaters Los Angeles, CA, United States | ||
IPO Launch date 2024-12-16 | CEO & Director Mr. Zaid Pardesi | ||
Sector Financial Services | Industry Shell Companies | Full time employees - | |
Full time employees - | |||
Oaktree Acquisition Corp. III Life Sciences does not have significant operations. The company focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities. It intends to target companies in the biopharmaceutical, medical devices, diagnostics, and specialized healthcare services sectors in North America and Europe. The company was incorporated in 2024 and is based in Los Angeles, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.